Blood plasma adipomyokine levels and proteinaseinhibitory activity in sarcopenic obesity

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: The search for diagnostic markers reflecting muscle function, protein catabolism, and adipose tissue metabolism in sarcopenia is an important medical problem.

AIM: To assess the levels of asprosin (adipokine), meteorinlike protein (myokine), and proteinaseinhibitory activity in blood plasma, and their relationship with metabolic parameters and sarcopenia criteria in sarcopenic obesity and during the presarcopenic phase.

METHODS: The study included 50 participants (38 women, 12 men) aged 45–85 years. Of these, 11 had sarcopenia (reduced strength and mass), 16 had presarcopenia (reduced strength), and 23 served as controls (no strength or mass loss). We measured asprosin, meteorinlike protein, elastase and trypsinlike proteinase activity, and alpha1proteinase inhibitor in plasma.

RESULTS: In sarcopenic obesity, asprosin correlated positively with fat mass (rs = 0.73, p = 0.012) and negatively with muscle strength (rs = −0.81, p = 0.023). Asprosin was higher in sarcopenia without obesity than in sarcopenic obesity: 9.200 (8.500; 9.300) vs 7.100 (6.000; 7.900) ng/mL (p = 0.045). Meteorinlike protein exceeded the upper reference limit (179–1990 pg/mL) in 50% of controls (up to 2191–2871 pg/mL) and 25% of presarcopenic participants (up to 2275–4647 pg/mL). In sarcopenic obesity, meteorinlike protein correlated negatively with Cpeptide (rs = −0.74, p = 0.005) and HOMAIR (rs = −0.79, p = 0.011). In controls, meteorinlike protein was lower in hypertensive participants, while both meteorinlike protein and asprosin were lower in type 2 diabetes. Proteinaseinhibitor imbalance in presarcopenia included increased trypsinlike activity (1.5fold) and decreased elastaselike activity (23%). Trypsinlike activity correlated with SARCF score (rs = 0.69, p = 0.02) and reduced performance. Higher alpha1proteinase inhibitor was associated with lower strength (rs = −0.62, p = 0.03) and muscle mass (rs = −0.63, p = 0.04) in controls, and with slower gait speed (rs = −0.9, p = 0.02) in presarcopenic obese participants.

CONCLUSION: Adipomyokine dysfunction and plasma proteinaseinhibitor imbalance, combined with metabolic disturbances, may play a role in the development of sarcopenic obesity.

Full Text

Restricted Access

About the authors

Liudmila V. Spirina

Siberian State Medical University

Author for correspondence.
Email: spirinalvl@mail.ru
ORCID iD: 0000-0002-5269-736X
SPIN-code: 1336-8363

MD, Dr. Sci. (Medicine), Head, Depart. of Biochemistry and Molecular Biology with a Course in Clinical Laboratory Diagnostics

Russian Federation, 2 Moscowski Trakt st, Tomsk, 634050

Valeria A. Shokalo

Siberian State Medical University

Email: valeriya_s@internet.ru
ORCID iD: 0009-0004-2789-8268

student, Depart. of Medical Biology

Russian Federation, Tomsk

Olga E. Akbasheva

Siberian State Medical University

Email: akbashoe@yandex.ru
ORCID iD: 0000-0003-0680-8249
SPIN-code: 8042-6940

MD, Dr. Sci. (Medicine), Professor, Depart. of Biochemistry and Molecular Biology with a course in Clinical Laboratory Diagnostics

Russian Federation, Tomsk

Denis A. Dyakov

Siberian State Medical University

Email: den66431511@yandex.ru
ORCID iD: 0000-0001-8667-9306
SPIN-code: 3029-3824

Senior Teacher, Depart. of Biochemistry and Molecular Biology with a course in Clinical Laboratory Diagnostics

Russian Federation, Tomsk

Lyudmila M. Shuliko

Siberian State Medical University

Email: ludmila.shuliko.15@gmail.com
ORCID iD: 0000-0001-5299-2097
SPIN-code: 2367-0385

Laboratory Assistant, Depart. of Pediatrics with a course in endocrinology

Russian Federation, Tomsk

Dmitry A. Svarovsky

Siberian State Medical University

Email: svarovsky.d.a@gmail.com
ORCID iD: 0000-0002-8985-009X
SPIN-code: 4131-8608

Assistant Lecturer, Depart. of Biochemistry and Molecular Biology with a course in Clinical Laboratory Diagnostics

Russian Federation, Tomsk

Iulia G. Samoilova

Siberian State Medical University

Email: samoilova_y@inbox.ru
ORCID iD: 0000-0002-2667-4842
SPIN-code: 8644-8043

MD, Dr. Sci. (Medicine), Professor, Depart. of Pediatrics with a Course in Endocrinology, Head, Clinical Research Center

Russian Federation, Tomsk

Maria V. Matveeva

Siberian State Medical University

Email: matveeva.mariia@yandex.ru
ORCID iD: 0000-0001-9966-6686
SPIN-code: 3913-5419

MD, Dr. Sci. (Medicine), Assistant Professor, Professor, Depart. of Pediatrics with a Course in Endocrinology

Russian Federation, Tomsk

Jude I. Ogieuhi

Siberian State Medical University

Email: jude.ogieuhi@gmail.com
ORCID iD: 0009-0003-9465-0089

postgraduate, Depart. of Biochemistry and Molecular Biology with a course in Clinical Laboratory Diagnostics

Russian Federation, Tomsk

Diana L. Shilova

Siberian State Medical University

Email: shilova.202@mail.ru
ORCID iD: 0009-0001-3846-7066

student, Depart. of Medical Biology

Russian Federation, Tomsk

References

  1. Donini LM, Busetto L, Bischoff SC, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022;15(3):321–335. doi: 10.1159/000521241 EDN: VHNMZB
  2. Najm A, Niculescu AG, Grumezescu AM, Beuran M. Emerging Therapeutic Strategies in Sarcopenia: An Updated Review on Pathogenesis and Treatment Advances. Int J Mol Sci. 2024;25(8):4300. doi: 10.3390/ijms25084300 EDN: LKRKRU
  3. Kurmaev DP, Bulgakova SV, Treneva EV, et al. Sarcopenic obesity and metabolic disorders in ageing. Experimental and Clinical Gastroenterology. 2025;(3):134–147. doi: 10.31146/1682-8658-ecg-235-3-134-147 EDN: QQWYBR
  4. Gizatullina RR, Gafuryanova EM, Zhamankulova DG, Tyurin AV. Changes in body composition: the role of interleukins and adipokines (literature review). Russian Medical Inquiry. 2025;9(10):726–734. doi: 10.32364/2587-6821-2025-9-10-5 EDN: ENMLNH
  5. Kochlik B, Franz K, Henning T, et al. Frailty is characterized by biomarker patterns reflecting inflammation or muscle catabolism in multi-morbid patients. J Cachexia Sarcopenia Muscle. 2023;14(1):157–166. doi: 10.1002/jcsm.13118 EDN: CFVDGS
  6. Vasyukova OV, Kasyanova YuV, Okorokov PL, Bezlepkina OB. Myokines and adipomyokines: inflammatory mediators or unique molecules of targeted therapy for obesity? Problems of Endocrinology. 2021;67(4):36–45. doi: 10.14341/probl12779 EDN: TGAWYG
  7. Farrag M, Ait Eldjoudi D, González-Rodríguez M, et al. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol. 2023;13:1101091. doi: 10.3389/fendo.2022.1101091 EDN: FHLZSK
  8. Keskin T, Erden Y, Tekin S. Intracerebroventricular asprosin administration strongly stimulates hypothalamic-pituitary-testicular axis in rats. Mol Cell Endocrinol. 2021;538:111451. doi: 10.1016/j.mce.2021.111451 EDN: ZXPRLE
  9. Sünnetçi Silistre E, Hatipoğl HU. Increased serum circulating asprosin levels in children with obesity. Pediatr Int. 2020;62:467–476. doi: 10.1111/ped.14176 EDN: EYVPYB
  10. Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018:9471583. doi: 10.1155/2018/9471583
  11. Kantorowicz M, Szymura J, Szygula Z, et al. Nordic Walking at maximal fat oxidation intensity decreases circulating asprosin and visceral obesity in women with metabolic disorders. Front Physiol. 2021;12:726783. doi: 10.3389/fphys.2021.726783 EDN: KJJFBI
  12. Lee DE, McKay L, Bareja A, et al. Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro/adipogenic progenitor signaling. Nat Commun. 2022;13(1):7613. doi: 10.1038/s41467-022-35390-3 EDN: QEPLHQ
  13. El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract. 2019;150:57–63. doi: 10.1016/j.diabres.2019.02.026
  14. Cavli C, Önalan E, Yakar B, et al. Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance. Fam Pract Palliat Care. 2022;7(5):137–141. doi: 10.22391/fppc.1130758
  15. Shatskaya OA, Bondarenko IZ, Kushnarenko SS. Changes in skeletal muscle in diabetes mellitus. Medical Council. 2024;(16):148–153. doi: 10.21518/ms2024-376 EDN: DEMHAX
  16. Alizadeh H. Meteorin-like protein (Metrnl): A metabolic syndrome biomarker and an exercise mediator. Cytokine. 2022;157:155952. doi: 10.1016/j.cyto.2022.155952 EDN: IJRKTC
  17. Wang ZY, Li YM, Yan JJ, et al. Low serum Metrnl levels are associated with increased risk of sarcopenia in the older adults. Eur Geriatr Med. 2024;15(6):1849–1857. doi: 10.1007/s41999-024-01074-y EDN: SLADVK
  18. Bae JY. Aerobic exercise increases meteorin-like protein in muscle and adipose tissue of chronic high-fat diet-induced obese mice. Biomed Res Int. 2018;2018:6283932. doi: 10.1155/2018/6283932
  19. Gao S, Zuo X, Liu D, et al. The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies. Arthritis Res Ther. 2018;20(1):134. doi: 10.1186/s13075-018-1632-x EDN: RRNSHM
  20. Kietsiriroje N, Ajjan RA, Grant PJ. Hemostatic abnormalities associated with diabetes and their clinical implications. In: Cardiovascular Endocrinology and Metabolism. Eckel RH, McGill JB, editors. Academic Press; 2023. P. 199–220. doi: 10.1016/B978-0-323-99991-5.00005-X
  21. Soma P, Swanepoel AC, Bester J, Pretorius E. Tissue factor levels in type 2 diabetes mellitus. Inflamm Res. 2017;66(5):365–368. doi: 10.1007/s00011-017-1030-x EDN: MEIUOM
  22. Gueugneau M, d'Hose D, Barbé C, et al. Increased Serpina3n release into circulation during glucocorticoid-mediated muscle atrophy. J Cachexia Sarcopenia Muscle. 2018;9(5):929–946. doi: 10.1002/jcsm.12315
  23. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. 2013;6(1):25–39. doi: 10.1242/dmm.010389 EDN: RHYIQR
  24. Tjondrokoesoemo A, Schips T, Kanisicak O, et al. Genetic overexpression of Serpina3n attenuates muscular dystrophy in mice. Hum Mol Genet. 2016;25(6):1192–1202. doi: 10.1093/hmg/ddw005
  25. Gueugneau M, d'Hose D, Barbé C, et al. Increased Serpina3n release into circulation during glucocorticoid-mediated muscle atrophy. J Cachexia Sarcopenia Muscle. 2018;9(5):929–946. doi: 10.1002/jcsm.12315
  26. Berns SA, Sheptulina AF, Mamutova EM, et al. Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria. Cardiovascular Therapy and Prevention. 2023;22(6):3576. doi: 10.15829/1728-8800-2023-3576 EDN: OWOAYO
  27. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531–532. doi: 10.1016/j.jamda.2013.05.018
  28. Sattler MC, Jaunig J, Tösch C, et al. Current Evidence of Measurement Properties of Physical Activity Questionnaires for Older Adults: An Updated Systematic Review. Sports Med. 2020;50(7):1271–1315. doi: 10.1007/s40279-020-01268-x EDN: GEYYGI
  29. de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med. 2014;276(4):311–335. doi: 10.1111/joim.12239
  30. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169 EDN: OIPUXJ
  31. Nartikova VF, Paskhina TS. A unified method for determining the activity of alpha1-proteinase inhibitor, alpha2-macroglobulin in human blood serum. Biomeditsinskaya Khimiya. 1989;25(4):494–499. (In Russ.)
  32. Ogloblina OG, Platonova LV, Paskhina TS. Measuring of activity of trypsin and elastase similar proteases of leucocytes and activity of acid proof inhibiters in bronchial region. Moscow: Publishing House of Moscow State University; 1984. 14 p. (In Russ.) EDN: RNRVYH
  33. Gao Y, Huang Y, An R, et al. Risk factors for sarcopenia in community setting across the life course: A systematic review and a meta-analysis of longitudinal studies. Arch Gerontol Geriatr. 2025;133:105807. doi: 10.1016/j.archger.2025.105807 EDN: WUDOIS
  34. Dodds RM, Roberts HC, Cooper C, et al. The Epidemiology of Sarcopenia. J Clin Densitom. 2015;18(4):461–466. doi: 10.1016/j.jocd.2015.04.012
  35. Drapkina OM, Maksimova OA, Sheptulina AF, Dzhioeva ON. Bioimpedance analysis of body composition: what should general practitioner know? Russian Journal of Preventive Medicine. 2022;25(10):91–96. doi: 10.17116/profmed20222510191 EDN: UQJOPW
  36. Wang M, Yin C, Wang L, et al. Serum Asprosin Concentrations Are Increased and Associated with Insulin Resistance in Children with Obesity. Ann Nutr Metab. 2019;75(4):205-212. doi: 10.1159/000503808
  37. Gozel N, Kilinc F. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin. Endokrynol Pol. 2021;72(1):37–43. doi: 10.5603/EP.a2020.0059 EDN: WLMXVJ
  38. Lee JO, Byun WS, Kang MJ, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting ampkα2. FEBS J. 2020;287(10):2087–2104. doi: 10.1111/febs.15301 EDN: OISEDK
  39. Hu W, Wang R, Sun B. Meteorin-like ameliorates β cell function by inhibiting β cell apoptosis of and promoting β cell proliferation via activating the wnt/β-catenin pathway. Front Pharmacol. 2021;12:627147. doi: 10.3389/fphar.2021.627147 EDN: YFIXSE
  40. Hu C, Zhang X, Song P, et al. Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating camp/pka/sirt1 pathway. Redox Biol. 2020;37:101747. doi: 10.1016/j.redox.2020.101747 EDN: MCVODA
  41. Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64(11):1183–1189. doi: 10.1093/gerona/glp097
  42. Witham MD, Granic A, Pearson E, et al. Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia-A Narrative Review. Drugs Aging. 2023;40(8):703–719. doi: 10.1007/s40266-023-01042-4 EDN: CYQEXT
  43. Kakehi S, Wakabayashi H, Inuma H, et al. Rehabilitation nutrition and exercise therapy for sarcopenia. World J Mens Health. 2022;40(1):1–10. doi: 10.5534/wjmh.200190 EDN: XNRRKD
  44. Bai X, Hippensteel J, Leavitt A, et al. Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. Med Hypotheses. 2021;146:110394. doi: 10.1016/j.mehy.2020.110394 EDN: AOAPEF
  45. McCarthy C, Saldova R, Wormald MR, et al. The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res. 2014;13(7):3131–3143. doi: 10.1021/pr500146y
  46. Marando M, Rayroux C, Bergeron A. Alpha-1 antitrypsin deficiency. Rev Med Suisse. 2022;18(804):2169–2174. (In French) doi: 10.53738/REVMED.2022.18.804.2169 EDN: EXOQIC

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2026 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07